Screener
Ligand Pharmaceuticals LGND Development and Licensing of Biopharmaceutical Assets — Stock-Based Comp
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 |
|---|---|---|---|---|
| Total revenues and income | $63,693 | $47,627 | $115,415 | $92,960 |
| Share-based compensation | (13,653) | (9,997) | (24,249) | (17,833) |
| Other segment items: | ||||
| Amortization of intangibles | (8,097) | (8,258) | (16,194) | (16,515) |
| Depreciation of property and equipment | (118) | (264) | (237) | (777) |
| Interest income | 7,298 | 1,621 | 13,953 | 3,392 |
| Interest expense | (1,748) | (1,153) | (3,495) | (2,020) |
| Other * | 1,133 | (24,729) | (50,030) | (96,811) |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — stock-based comp?
- Ligand Pharmaceuticals (LGND) reported development and licensing of biopharmaceutical assets — stock-based comp of $13.65M in Q2 2026.
- How has Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — stock-based comp changed year-over-year?
- Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — stock-based comp increased by 36.6% year-over-year, from $10M to $13.65M.
- What is the long-term trend for Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — stock-based comp?
- Over 3 years (2022 to 2025), Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — stock-based comp has grown at a -8.1% compound annual growth rate (CAGR), from $60.29M to $46.85M.
- What does development and licensing of biopharmaceutical assets — stock-based comp mean?
- This metric measures the non-cash expense recognized for equity-based awards granted to employees and service providers within the development and licensing segment. It reflects the cost of aligning human capital incentives with long-term shareholder value creation. Monitoring this expense is essential for understanding the true economic cost of talent acquisition and retention within the segment.
Ask your AI about Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude